Form 4: UTHR Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Judy D. Olian sold 200 shares of common stock for $530 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Judy D. Olian, a Director of United Therapeutics Corp (UTHR), reported the sale of 200 shares of common stock.
• The transaction occurred on March 23, 2026, at a price of $530 per share.
• This sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on November 4, 2025.
• Following this transaction, Ms. Olian beneficially owns 4,245 shares of United Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was pre-planned under a 10b5-1 plan, which typically mitigates concerns about opportunistic insider selling and does not reflect a change in company fundamentals.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales executed under pre-arranged 10b5-1 plans are common practice for corporate executives and directors to manage personal finances while adhering to insider trading regulations. This specific transaction does not inherently signal a change in the company's operational or strategic direction within the biotechnology or pharmaceutical industry.

Related Party Transactions

• Judy D. Olian, a Director of United Therapeutics Corp, sold 200 shares of common stock to the open market. This is a related party transaction as Ms. Olian is an insider.

Stakeholder Impact

• Shareholders: The sale of 200 shares by a director is a minor transaction relative to the company's overall market capitalization and is unlikely to have a significant direct impact on other shareholders. The pre-arranged nature of the sale under a 10b5-1 plan suggests it is for personal financial planning rather than a signal about the company's future performance.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider sale by a director under a 10b5-1 plan. Such transactions are typically for personal financial management and do not provide new fundamental information about the company's prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Sale, Judy D. Olian, Director, 10b5-1 Plan, Common Stock